What Researchers Did
Researchers reviewed experimental studies, both lab and animal research plus a limited number of clinical trials, examining whether HBOT could make standard glioma (brain cancer) treatment more effective.
What They Found
Glioma tumors are naturally low in oxygen (hypoxic), which makes them more resistant to radiation and chemotherapy. HBOT may temporarily raise oxygen levels inside tumors, potentially reducing that resistance. However, the review found no consistent clinical evidence proving HBOT improves survival in glioma patients, with only preclinical (animal/lab) studies showing clear promise.
What This Means for Canadian Patients
For Canadians with glioma, one of the deadliest brain cancers, with only about 10% surviving 5 years, HBOT is not yet a proven add-on treatment. Patients interested in HBOT as a complement to radiation or chemotherapy should discuss it with their oncologist, as the evidence is still at an early stage.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a narrative review of mostly preclinical studies, so conclusions cannot be applied directly to human patients without randomized clinical trial evidence.